In-vitro and in-vivo comparison of T-OA microemulsions and solid dispersions based on EPDC. (February 2015)
- Record Type:
- Journal Article
- Title:
- In-vitro and in-vivo comparison of T-OA microemulsions and solid dispersions based on EPDC. (February 2015)
- Main Title:
- In-vitro and in-vivo comparison of T-OA microemulsions and solid dispersions based on EPDC
- Authors:
- Hou, Peng
Cao, Sali
Ni, Jian
Zhang, Tao
Cai, Zhengjun
Liu, Juanjuan
Wang, Ye
Wang, Penglong
Lei, Haimin
Liu, Yong - Abstract:
- <abstract> <title>Abstract</title> <p>The goal of this study was to enhance the absorption of a new water-insoluble antitumor lead compound, T-OA (3β-hydroxyolea-12-en-28-oic acid-3, 5, 6-trimethylpyrazin-2-methyl ester). Early-stage preparation discovery concept (EPDC) was employed in this study. Based on this concept, a microemulsion system was chosen as the method of improving bioavailability. The solubility of T-OA was checked in different oils, surfactants and cosurfactants. Ternary phase diagrams were constructed to evaluate the microemulsion domain. Developed high-performance liquid chromatography method was used to determine drug content. The transparent o/w microemulsion formulation composed of oleic acid (oil), Tween 80 (surfactant), ethanol (co-surfactant) and water enhanced the solubility of T-OA up to 20 mg/mL. It was characterized in terms of appearance, content, viscosity, zeta potential, conductivity, morphology and particle size. The particle size distribution, viscosity, conductivity and zeta potential were found to be 70 nm, 15.57 MPa s, 44.1 μS cm<sup>−1</sup> and −0.174, respectively. Oral bioavailability of T-OA microemulsion and oleic acid solution were checked by using rat model. Contrast to the solid dispersion and proto drug, the area-under-the-curve (AUC) of T-OA microemulsion and oleic acid solution were significantly enhanced. The relative bioavailability of T-OA microemulsion was found to be 5654.7%, which is 57-fold higher than the pure drug.<abstract> <title>Abstract</title> <p>The goal of this study was to enhance the absorption of a new water-insoluble antitumor lead compound, T-OA (3β-hydroxyolea-12-en-28-oic acid-3, 5, 6-trimethylpyrazin-2-methyl ester). Early-stage preparation discovery concept (EPDC) was employed in this study. Based on this concept, a microemulsion system was chosen as the method of improving bioavailability. The solubility of T-OA was checked in different oils, surfactants and cosurfactants. Ternary phase diagrams were constructed to evaluate the microemulsion domain. Developed high-performance liquid chromatography method was used to determine drug content. The transparent o/w microemulsion formulation composed of oleic acid (oil), Tween 80 (surfactant), ethanol (co-surfactant) and water enhanced the solubility of T-OA up to 20 mg/mL. It was characterized in terms of appearance, content, viscosity, zeta potential, conductivity, morphology and particle size. The particle size distribution, viscosity, conductivity and zeta potential were found to be 70 nm, 15.57 MPa s, 44.1 μS cm<sup>−1</sup> and −0.174, respectively. Oral bioavailability of T-OA microemulsion and oleic acid solution were checked by using rat model. Contrast to the solid dispersion and proto drug, the area-under-the-curve (AUC) of T-OA microemulsion and oleic acid solution were significantly enhanced. The relative bioavailability of T-OA microemulsion was found to be 5654.7%, which is 57-fold higher than the pure drug. Improved T-OA solubility in microemulsion was found sustained 48 h in dilution study. While the solid dispersion may precipitate under the gastrointestinal circumstance based on dilution results. The <italic>in-vivo</italic> and <italic>in-vitro</italic> results indicated that, compare to improve the solubility, it is more important to maintain and prolong the T-OA dissolved status, for improvement of the <italic>in-vivo</italic> absorption.</p> </abstract> … (more)
- Is Part Of:
- Drug development and industrial pharmacy. Volume 41:Number 2(2015:Feb.)
- Journal:
- Drug development and industrial pharmacy
- Issue:
- Volume 41:Number 2(2015:Feb.)
- Issue Display:
- Volume 41, Issue 2 (2015)
- Year:
- 2015
- Volume:
- 41
- Issue:
- 2
- Issue Sort Value:
- 2015-0041-0002-0000
- Page Start:
- 263
- Page End:
- 271
- Publication Date:
- 2015-02
- Subjects:
- Pharmaceutical chemistry -- Periodicals
Pharmaceutical industry -- Periodicals
Drug Industry -- Periodicals
Technology, Pharmaceutical -- Periodicals
615.05 - Journal URLs:
- http://informahealthcare.com/loi/ddi ↗
http://informahealthcare.com ↗ - DOI:
- 10.3109/03639045.2013.858739 ↗
- Languages:
- English
- ISSNs:
- 0363-9045
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3629.116000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 4088.xml